| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Financial Officer
1 company
Hans van Houte is Chief Financial Officer at NRIX. From February 2021 to October 2026, the filings on record show 0 open-market purchases and 36 sales. Hans van Houte's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.2M at current prices.
Historically, Hans van Houte's trades have earned a middling insider score of 56/100 across 32 rated trades. Over a 12-month horizon, 52.0% of those trades were profitable, with an average 12-month return of -19.2%.
The NRIX filings lean toward selling, a net 207,123 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 31, 2022 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 739 | $12.88 | $9,518.69 | -1.0% | -6.8% | -56.1% | |
| Aug 1, 2022 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 752 | $15.67 | $11,783.84 | -1.0% | -17.4% | -38.4% | |
| May 2, 2022 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 697 | $11.75 | $8,189.75 | -24.2% | +28.8% | -21.4% | |
| Feb 24, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 35,419 | $39.90 | $1,413,218.10 | - | - | - | |
| Feb 22, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 5,330 | $39.93 | $212,839.16 | - | - | - | |
| Feb 18, 2021 | NRIX Nurix Therapeutics, Inc. | Chief Financial Officer | Sale+OE | 13,583 | $35.46 | $481,621.05 | - | - | - |